BioPharma Clinical Trials
Everest Medicines Secures China Approval for CARDAMYST to Treat Acute PSVT Episodes
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
September 04, 2026 | News
Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis
Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...
September 03, 2026 | News
Singapore Becomes First ASEAN Market to Subsidise Vutrisiran for ATTR Amyloidosis
"From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75%[1],[2]" "HELIOS-A and B provide strong ...
September 02, 2026 | News
Ascletis Doses First Patient in Global Phase III Programme for Oral GLP-1 Obesity Drug ASC30
- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and...
September 01, 2026 | News
HiRO and Differentia Join Forces to Advance AI-Powered Clinical Trial Simulation and Digital Twins
Memorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities The partnership unites global clinic...
August 31, 2026 | News
Sanyou Bio Launches AI-Powered Clicklinks to Accelerate Global Drug Discovery and Preclinical Development
Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Sanyou Bio"), announced the official launch of Clicklinks, an AI-STAL and SAI-DA pow...
August 31, 2026 | News
HaemaLogiX Doses First Patient with KMCAR T-Cell Therapy in Phase 1 Multiple Myeloma Trial
First patient safely dosed in Phase 1 KOALA trial evaluating KMCAR™ T-cell therapy in patients with relapsed/refractory kappa-restricted multiple m...
August 27, 2026 | News
WuXi XDC H1 2026 Revenue Jumps 37% to RMB 3.7 Bn on Strong Bioconjugate Demand
Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2]...
August 26, 2026 | Company results
Antengene’s ATG-201 Wins Australian Clearance for Phase I Autoimmune Disease Trial
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...
August 26, 2026 | News
Pulnovo Medical Enrols First Patients in PULSE-LHD Trial for Pulmonary Hypertension
Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), announced the enrollment of the f...
August 24, 2026 | News
Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1
Akeso, Inc. announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearanc...
August 24, 2026 | News
Leads Biolabs’ Opamtistomig NDA Accepted in China for Advanced EP-NEC
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China'...
August 24, 2026 | News
CureGene Doses First Subject in Australia Phase I Trial of Oral Metabolic Drug CG-0416
CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist...
August 24, 2026 | News
Ingenia Therapeutics Debuts on KOSDAQ to Accelerate Next-Gen Vascular Antibody Pipeline
Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that its shares have begun t...
August 21, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
